DK3678668T3 - ENPP1-inhibitorer og deres anvendelse til behandling af kræft - Google Patents
ENPP1-inhibitorer og deres anvendelse til behandling af kræft Download PDFInfo
- Publication number
- DK3678668T3 DK3678668T3 DK18779884.8T DK18779884T DK3678668T3 DK 3678668 T3 DK3678668 T3 DK 3678668T3 DK 18779884 T DK18779884 T DK 18779884T DK 3678668 T3 DK3678668 T3 DK 3678668T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- treatment
- enpp1 inhibitors
- enpp1
- inhibitors
- Prior art date
Links
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556117P | 2017-09-08 | 2017-09-08 | |
| PCT/US2018/050018 WO2019051269A1 (en) | 2017-09-08 | 2018-09-07 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3678668T3 true DK3678668T3 (da) | 2024-04-08 |
Family
ID=63714052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18779884.8T DK3678668T3 (da) | 2017-09-08 | 2018-09-07 | ENPP1-inhibitorer og deres anvendelse til behandling af kræft |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11701371B2 (da) |
| EP (2) | EP4327882A3 (da) |
| JP (2) | JP7292740B2 (da) |
| KR (2) | KR20240151869A (da) |
| CN (2) | CN111372587B (da) |
| AU (2) | AU2018330188C1 (da) |
| BR (1) | BR112020004559A2 (da) |
| CA (1) | CA3074268A1 (da) |
| DK (1) | DK3678668T3 (da) |
| EA (1) | EA202090595A1 (da) |
| ES (1) | ES2975183T3 (da) |
| HU (1) | HUE066413T2 (da) |
| IL (3) | IL311010A (da) |
| MA (1) | MA50082A (da) |
| MX (2) | MX2020002646A (da) |
| PL (1) | PL3678668T3 (da) |
| SG (1) | SG11202001728YA (da) |
| WO (1) | WO2019051269A1 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3902787A4 (en) * | 2018-12-28 | 2022-12-28 | Riboscience LLC | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| PT3952995T (pt) | 2019-04-12 | 2023-10-25 | Riboscience Llc | Derivados bicíclicos de heteroarilo como inibidores da ectonucleótido piroposfatase fosfodiesterase 1 |
| BR112022004809A2 (pt) | 2019-09-16 | 2022-06-21 | Aten Porus Lifesciences Pvt Ltd | Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1 |
| CA3154475A1 (en) * | 2019-09-23 | 2021-04-01 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
| TW202140439A (zh) * | 2020-02-04 | 2021-11-01 | 美商史汀葛瑞醫療公司 | 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)之抑制劑及其使用方法 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CA3171648A1 (en) | 2020-02-18 | 2021-08-26 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN115362150A (zh) * | 2020-04-09 | 2022-11-18 | 贝达药业股份有限公司 | Enpp1抑制剂及其组合物和用途 |
| JP2023524821A (ja) * | 2020-05-04 | 2023-06-13 | ヴォラストラ セラピューティクス,インコーポレーテッド | Enpp1のイミノスルファノン阻害剤 |
| KR102682428B1 (ko) | 2020-05-08 | 2024-07-05 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 |
| EP4148046A4 (en) | 2020-05-08 | 2024-07-24 | Txinno Bioscience Inc. | NEW PHTHALAZINE DERIVATIVE WITH ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE INHIBITING ACTIVITY AND USE THEREOF |
| US12091412B2 (en) | 2020-06-16 | 2024-09-17 | Volastra Therapeutics, Inc. | Heterocyclic inhibitors of ENPP1 |
| CA3191172A1 (en) | 2020-09-03 | 2022-03-10 | Immunesensor Therapeutics, Inc. | Quinoline cgas antagonist compounds |
| EP4236928A4 (en) * | 2020-10-30 | 2024-08-28 | 1Cbio, Inc. | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND THEIR USES |
| WO2022125613A1 (en) * | 2020-12-09 | 2022-06-16 | Stingray Therapeutics, Inc. | Phosphonates as inhibitors of enpp1 and cdnp |
| CN116600813A (zh) * | 2020-12-09 | 2023-08-15 | 斯汀格瑞治疗股份有限公司 | 作为enpp1和cdnp抑制剂的膦酸盐 |
| KR102720206B1 (ko) | 2020-12-29 | 2024-10-21 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도 |
| AU2021412688B2 (en) | 2020-12-29 | 2025-06-12 | Txinno Bioscience Inc. | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| WO2022164249A1 (ko) | 2021-01-29 | 2022-08-04 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도 |
| KR102686866B1 (ko) | 2021-01-29 | 2024-07-19 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도 |
| US20240209005A1 (en) * | 2021-03-16 | 2024-06-27 | Riboscience Llc | Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| CN115536696B (zh) * | 2021-06-29 | 2023-07-14 | 上海齐鲁制药研究中心有限公司 | Enpp1抑制剂 |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| WO2023035001A1 (en) * | 2021-09-03 | 2023-03-09 | Angarus Therapeutics, Inc. | Enpp1 inhibitors and immune cells expressing chimeric antigen receptors |
| EP4422639A4 (en) * | 2021-10-29 | 2025-09-03 | Angarus Therapeutics Inc | ENPP1 INHIBITORS AS METASTASIS INHIBITORS |
| JP2025507820A (ja) | 2022-03-02 | 2025-03-21 | イミューンセンサー セラピューティクス、インコーポレイテッド | キノリンcGasアンタゴニスト化合物 |
| CN118488950A (zh) * | 2022-04-11 | 2024-08-13 | 上海齐鲁制药研究中心有限公司 | Enpp1抑制剂 |
| CN114767863B (zh) * | 2022-04-29 | 2024-01-30 | 西北工业大学 | 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用 |
| WO2023212154A1 (en) | 2022-04-29 | 2023-11-02 | Petragen, Inc. | Inhibitors of enpp1 and modulation of bone growth |
| CN119677742A (zh) * | 2022-08-01 | 2025-03-21 | 斯拉瓦蒂人工智能科技私人有限公司 | 一种新型外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)抑制剂及其用途 |
| WO2024213932A1 (en) * | 2023-04-11 | 2024-10-17 | The Hong Kong University Of Science And Technology | Driving axon regeneration by novel enpp1 inhibitors |
| WO2024216211A2 (en) * | 2023-04-14 | 2024-10-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of inhibiting tumor progression and metastasis by inhibition of enpp1 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA228044A (en) | 1923-01-16 | Thomas Noble Boughton | Die for forming bolts | |
| CA190896A (en) | 1919-02-24 | 1919-06-17 | Josephat C. Bergeron | Advertising device |
| DE3319795A1 (de) | 1983-06-01 | 1984-12-06 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von phosphonsaeureestern |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| CN1113066C (zh) | 1995-04-21 | 2003-07-02 | 帝国脏器制药株式会社 | 新型肽衍生物 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US6960580B2 (en) * | 2001-03-08 | 2005-11-01 | Millennium Pharmaceuticals, Inc. | Nitrogenous heterocyclic substituted quinoline compounds |
| US20040101840A1 (en) * | 2001-04-27 | 2004-05-27 | Chung Leland W.K. | Identification, cloning and characterization of a novel pc-1 gene differentially expressed in prostate cells and tissues |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| DK1847539T3 (da) | 2002-12-24 | 2009-11-09 | Astrazeneca Ab | Quinazolin-derivater |
| US20070004763A1 (en) | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
| US10543207B2 (en) | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| PL2621923T3 (pl) * | 2010-09-29 | 2017-08-31 | Intervet International B.V. | Związki n-heteroarylu z mostkami cyklicznymi do leczenia chorób pasożytniczych |
| WO2013096680A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| ES2822584T3 (es) | 2013-05-03 | 2021-05-04 | Univ California | Inducción de dinucleótidos cíclicos del interferón tipo I |
| CA2904536A1 (en) | 2013-05-18 | 2014-11-27 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| CN107207465B (zh) * | 2014-09-22 | 2021-09-10 | 财团法人卫生研究院 | 杂环化合物及其用途 |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| CN105153153A (zh) | 2015-08-31 | 2015-12-16 | 吉林奥来德光电材料股份有限公司 | 一种新的芳香族胺类化合物及其制备与应用 |
| TWI659949B (zh) | 2016-05-16 | 2019-05-21 | 臺北醫學大學 | 組蛋白去乙醯酶6抑制劑及其用途 |
| EP3558319A4 (en) | 2016-12-22 | 2020-07-22 | AbbVie Inc. | COMPOSITIONS AND PROCESSES FOR IMPROVING OR INCREASING THE PRODUCTION OF TYPE I IFN |
| BR112019014335A2 (pt) | 2017-01-09 | 2020-02-27 | The Australian National University | Sinérgicos para pesticidas melhorados |
| US10518257B2 (en) | 2017-05-04 | 2019-12-31 | Exxonmobil Research And Engineering Company | Metal organic frameworks, their synthesis and use |
| WO2018229139A1 (en) | 2017-06-14 | 2018-12-20 | Fundación Para La Investigación Médica Aplicada | Novel compounds for use in cancer |
| CN111315723A (zh) | 2017-08-31 | 2020-06-19 | 艾伯维公司 | 膜外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制剂及其用途 |
| AU2020214628B2 (en) | 2019-02-01 | 2025-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | ENPP1 inhibitors and methods of modulating immune response |
| CN114437128B (zh) * | 2022-01-28 | 2023-12-19 | 中国科学院长春应用化学研究所 | 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用 |
-
2018
- 2018-09-07 EP EP24150802.7A patent/EP4327882A3/en not_active Withdrawn
- 2018-09-07 KR KR1020247033122A patent/KR20240151869A/ko active Pending
- 2018-09-07 JP JP2020513331A patent/JP7292740B2/ja active Active
- 2018-09-07 MX MX2020002646A patent/MX2020002646A/es unknown
- 2018-09-07 CN CN201880063793.8A patent/CN111372587B/zh active Active
- 2018-09-07 EP EP18779884.8A patent/EP3678668B1/en active Active
- 2018-09-07 IL IL311010A patent/IL311010A/en unknown
- 2018-09-07 AU AU2018330188A patent/AU2018330188C1/en active Active
- 2018-09-07 ES ES18779884T patent/ES2975183T3/es active Active
- 2018-09-07 PL PL18779884.8T patent/PL3678668T3/pl unknown
- 2018-09-07 SG SG11202001728YA patent/SG11202001728YA/en unknown
- 2018-09-07 KR KR1020207007008A patent/KR102715420B1/ko active Active
- 2018-09-07 IL IL302338A patent/IL302338B2/en unknown
- 2018-09-07 MA MA050082A patent/MA50082A/fr unknown
- 2018-09-07 HU HUE18779884A patent/HUE066413T2/hu unknown
- 2018-09-07 WO PCT/US2018/050018 patent/WO2019051269A1/en not_active Ceased
- 2018-09-07 US US16/645,300 patent/US11701371B2/en active Active
- 2018-09-07 DK DK18779884.8T patent/DK3678668T3/da active
- 2018-09-07 BR BR112020004559-4A patent/BR112020004559A2/pt not_active Application Discontinuation
- 2018-09-07 EA EA202090595A patent/EA202090595A1/ru unknown
- 2018-09-07 IL IL272948A patent/IL272948B2/en unknown
- 2018-09-07 CN CN202311760294.3A patent/CN117883449A/zh active Pending
- 2018-09-07 CA CA3074268A patent/CA3074268A1/en active Pending
-
2020
- 2020-03-06 MX MX2023007193A patent/MX2023007193A/es unknown
-
2022
- 2022-09-30 US US17/957,392 patent/US11707471B2/en active Active
-
2023
- 2023-05-16 US US18/197,877 patent/US20230277570A1/en active Pending
- 2023-05-31 JP JP2023089900A patent/JP7607969B2/ja active Active
-
2024
- 2024-01-10 AU AU2024200148A patent/AU2024200148A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
| DK3307727T3 (da) | Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft | |
| DK3368069T3 (da) | Anvendelse af myostatininhibitorer og kombinationsterapier | |
| DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| DK3452485T3 (da) | Arginasehæmmere og deres terapeutiske anvendelser | |
| DK3256218T3 (da) | Kdm1a-hæmmer og anvendelse deraf i terapi | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3331900T3 (da) | Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3325488T3 (da) | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer | |
| DK4234581T3 (da) | Terapeutiske antistoffer og deres anvendelse | |
| DK3322425T3 (da) | Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3860990T3 (da) | Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3621694T5 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
| DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| DK3601296T3 (da) | 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere |